Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 6,583 Shares of Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 6,583 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $43,381.97. Following the completion of the transaction, the chief financial officer now owns 93,546 shares in the company, valued at $616,468.14. The trade was a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Molly Henderson also recently made the following trade(s):

• On Thursday, December 19th, Molly Henderson sold 1,291 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $8.00, for a total value of $10,328.00.

Phathom Pharmaceuticals Trading Up 2.6 %

Shares of NASDAQ PHAT traded up $0.18 during midday trading on Thursday, hitting $7.17. The company’s stock had a trading volume of 649,136 shares, compared to its average volume of 943,045. The business’s 50 day moving average is $8.08 and its two-hundred day moving average is $12.53. Phathom Pharmaceuticals, Inc. has a 12-month low of $6.07 and a 12-month high of $19.71. The firm has a market cap of $490.28 million, a P/E ratio of -1.26 and a beta of 0.56.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its earnings results on Thursday, November 7th. The company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.57) by $0.25. The business had revenue of $16.35 million for the quarter, compared to the consensus estimate of $12.54 million. During the same quarter last year, the business posted ($0.76) earnings per share. On average, analysts predict that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. State Street Corp raised its stake in shares of Phathom Pharmaceuticals by 17.5% during the third quarter. State Street Corp now owns 922,788 shares of the company’s stock valued at $16,684,000 after acquiring an additional 137,539 shares in the last quarter. Eagle Asset Management Inc. increased its holdings in Phathom Pharmaceuticals by 25.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 455,196 shares of the company’s stock worth $7,675,000 after purchasing an additional 93,733 shares during the period. FMR LLC raised its position in Phathom Pharmaceuticals by 49,000.7% during the 3rd quarter. FMR LLC now owns 1,304,114 shares of the company’s stock valued at $23,578,000 after purchasing an additional 1,301,458 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Phathom Pharmaceuticals during the 3rd quarter valued at $7,952,000. Finally, Jennison Associates LLC lifted its holdings in shares of Phathom Pharmaceuticals by 112.7% in the 3rd quarter. Jennison Associates LLC now owns 5,866,389 shares of the company’s stock worth $106,064,000 after buying an additional 3,108,810 shares during the period. 99.01% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PHAT has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.